Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
Molineux
Graham
G
Amgen Inc, Thousand Oaks, CA, USA.
Newland
Adrian
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001565:Benzoates / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000266:history; D049671:History, 18th Century; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D051379:Mice; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000266:history; D011720:Pyrazoles / Q000627:therapeutic use; D011961:Receptors, Fc / Q000266:history / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000266:history / Q000627:therapeutic use*; D013926:Thrombopoietin / Q000266:history / Q000502:physiology / Q000627:therapeutic use*; D055815:Young Adult
D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag